Cara Therapeutics (CARA)

$5.32 -0.23 (-4.14%)
Market Cap 24.33M
Revenue (ttm) 7.14M
Net Income (ttm) -70.87M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -992.58%
Debt to Equity Ratio 0.00
Volume 237,100
Avg Vol 21,144
Day's Range N/A - N/A
Shares Out 4.57M
Stochastic %K 65%
Beta 0.41
Analysts Strong Sell
Price Target $96.04

Company Profile

Cara Therapeutics, Inc. operates as a biopharmaceutical company that focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica....

Industry: Biotechnology
Sector: Healthcare
Phone: (203) 406-3700
Address:
400 Atlantic Street, Suite 500, Stamford, United States
NoEmotionzTrade
NoEmotionzTrade Feb. 19 at 1:15 AM
AGAE is sitting at a valuation that doesn’t reflect its partnerships or cash position. 3M float cap is nothing. If buyers step in and shorts can’t find shares, this can squeeze toward .50 quickly. $TRVN $GRTX $CARA $ALBT
1 · Reply
liadanielle
liadanielle Feb. 10 at 9:29 PM
$CARA FBIO!!!! Hold this long and make your money back
0 · Reply
liadanielle
liadanielle Feb. 10 at 9:20 PM
$CARA Wow!! I made a lot of money on this stock 3 to 4 years ago buying and selling up and down. They had revolutionary ideas. But I guess they’re shit just don’t work.
0 · Reply
Buckwacker
Buckwacker Jan. 3 at 1:54 AM
$CARA this is down 540 percent in five years I lost 16 k They suck…
0 · Reply
Buckwacker
Buckwacker Dec. 15 at 8:18 PM
$CARA wholly shit!! I haven’t looked at this for a bout a year Reverse split horror show…. 🤦🏻‍♂️
0 · Reply
saudq1978
saudq1978 Oct. 22 at 4:59 PM
$CARA
0 · Reply
Bigprofits23
Bigprofits23 Oct. 16 at 2:06 PM
$CARA Is this the proverbial, “Dead Cat Bounce?”
0 · Reply
saudq1978
saudq1978 Oct. 14 at 4:32 AM
$CARA
0 · Reply
saudq1978
saudq1978 Oct. 14 at 4:32 AM
$CARA
0 · Reply
saudq1978
saudq1978 Oct. 14 at 4:31 AM
$CARA
0 · Reply
Latest News on CARA
Tvardi Therapeutics Announces Closing of Merger with Cara Therapeutics

Apr 15, 2025, 4:05 PM EDT - 11 months ago

Tvardi Therapeutics Announces Closing of Merger with Cara Therapeutics

TVRD

Cara Therapeutics Announces 1-for-3 Reverse Stock Split in Connection with the Proposed Merger with Tvardi Therapeutics

Apr 14, 2025, 11:50 AM EDT - 11 months ago

Cara Therapeutics Announces 1-for-3 Reverse Stock Split in Connection with the Proposed Merger with Tvardi Therapeutics

CARA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cara Therapeutics, Inc. - CARA

Feb 20, 2025, 5:25 PM EST - 1 year ago

CARA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cara Therapeutics, Inc. - CARA

Cara Therapeutics Announces Effective Date of 1-for-12 Reverse Stock Split

Dec 27, 2024, 7:00 AM EST - 1 year ago

Cara Therapeutics Announces Effective Date of 1-for-12 Reverse Stock Split

Cara Therapeutics and Tvardi Therapeutics Announce Entry into Merger Agreement

Dec 18, 2024, 7:00 AM EST - 1 year ago

Cara Therapeutics and Tvardi Therapeutics Announce Entry into Merger Agreement

These Cara Therapeutics Analysts Are No Longer Bullish: 'We See No Obvious Future Value Drivers'

Jun 13, 2024, 12:21 PM EDT - 1 year ago

These Cara Therapeutics Analysts Are No Longer Bullish: 'We See No Obvious Future Value Drivers'

Cara Therapeutics discontinues study on a neurological condition as drug fails

Jun 12, 2024, 4:19 PM EDT - 1 year ago

Cara Therapeutics discontinues study on a neurological condition as drug fails

Cara Therapeutics Announces Outcome of Part A of KOURAGE-1 Study Evaluating Oral Difelikefalin in Notalgia Paresthetica

Jun 12, 2024, 4:01 PM EDT - 1 year ago

Cara Therapeutics Announces Outcome of Part A of KOURAGE-1 Study Evaluating Oral Difelikefalin in Notalgia Paresthetica

Cara Therapeutics Reports First Quarter 2024 Financial Results

May 13, 2024, 4:01 PM EDT - 1 year ago

Cara Therapeutics Reports First Quarter 2024 Financial Results

Cara Therapeutics to Announce First Quarter 2024 Financial Results on May 13, 2024

May 6, 2024, 7:00 AM EDT - 1 year ago

Cara Therapeutics to Announce First Quarter 2024 Financial Results on May 13, 2024

Cara Therapeutics, Inc. (CARA) to Present at the 23rd Annual Needham Virtual Healthcare Conference

Apr 2, 2024, 9:02 AM EDT - 2 years ago

Cara Therapeutics, Inc. (CARA) to Present at the 23rd Annual Needham Virtual Healthcare Conference

Cara Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

Apr 2, 2024, 7:00 AM EDT - 2 years ago

Cara Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

Cara Therapeutics to Host Notalgia Paresthetica (NP) Virtual KOL Event on Wednesday, March 27, 2024

Mar 7, 2024, 7:00 AM EST - 2 years ago

Cara Therapeutics to Host Notalgia Paresthetica (NP) Virtual KOL Event on Wednesday, March 27, 2024

Cara Therapeutics, Inc. (CARA) Q4 2023 Earnings Call Transcript

Mar 4, 2024, 7:07 PM EST - 2 years ago

Cara Therapeutics, Inc. (CARA) Q4 2023 Earnings Call Transcript

Cara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results

Mar 4, 2024, 4:01 PM EST - 2 years ago

Cara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results

Cara Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024

Feb 12, 2024, 4:01 PM EST - 2 years ago

Cara Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024

Cara Therapeutics Prioritizes Late-Stage Notalgia Paresthetica Program and Extends Cash Runway into 2026

Jan 22, 2024, 7:00 AM EST - 2 years ago

Cara Therapeutics Prioritizes Late-Stage Notalgia Paresthetica Program and Extends Cash Runway into 2026

Cara Therapeutics Announces Outcome from Dose-Finding Part A of KIND 1 Study Evaluating Oral Difelikefalin for Moderate-to-Severe Pruritus in Patients with Atopic Dermatitis

Dec 18, 2023, 7:00 AM EST - 2 years ago

Cara Therapeutics Announces Outcome from Dose-Finding Part A of KIND 1 Study Evaluating Oral Difelikefalin for Moderate-to-Severe Pruritus in Patients with Atopic Dermatitis

Cara Therapeutics, Inc. (Cara) Q3 2023 Earnings Call Transcript

Nov 13, 2023, 7:20 PM EST - 2 years ago

Cara Therapeutics, Inc. (Cara) Q3 2023 Earnings Call Transcript

Cara Therapeutics Reports Third Quarter 2023 Financial Results

Nov 13, 2023, 4:01 PM EST - 2 years ago

Cara Therapeutics Reports Third Quarter 2023 Financial Results

Cara Therapeutics Announces up to $40.0 Million Non-Dilutive Financing Agreement with HealthCare Royalty

Nov 2, 2023, 7:00 AM EDT - 2 years ago

Cara Therapeutics Announces up to $40.0 Million Non-Dilutive Financing Agreement with HealthCare Royalty

Cara Therapeutics to Announce Third Quarter 2023 Financial Results on November 13, 2023

Oct 23, 2023, 7:00 AM EDT - 2 years ago

Cara Therapeutics to Announce Third Quarter 2023 Financial Results on November 13, 2023

Cara Therapeutics Announces Approval of KORSUVA® IV Injection Syringe in Japan for the Treatment of Pruritus in Hemodialysis Patients

Sep 25, 2023, 7:00 AM EDT - 2 years ago

Cara Therapeutics Announces Approval of KORSUVA® IV Injection Syringe in Japan for the Treatment of Pruritus in Hemodialysis Patients

Cara Therapeutics, Inc. (CARA) Q2 2023 Earnings Call Transcript

Aug 7, 2023, 6:13 PM EDT - 2 years ago

Cara Therapeutics, Inc. (CARA) Q2 2023 Earnings Call Transcript

Cara Therapeutics Reports Second Quarter 2023 Financial Results

Aug 7, 2023, 4:01 PM EDT - 2 years ago

Cara Therapeutics Reports Second Quarter 2023 Financial Results

Cara Therapeutics Appoints Helen M. Boudreau to Board of Directors

Aug 3, 2023, 7:00 AM EDT - 2 years ago

Cara Therapeutics Appoints Helen M. Boudreau to Board of Directors

Cara Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference

Aug 2, 2023, 7:00 AM EDT - 2 years ago

Cara Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference

Cara Therapeutics to Announce Second Quarter 2023 Financial Results on August 7, 2023

Jul 24, 2023, 7:00 AM EDT - 2 years ago

Cara Therapeutics to Announce Second Quarter 2023 Financial Results on August 7, 2023

Cara Therapeutics Faces Uncertainty Despite Potential Reimbursement Extension For Korsuva

Jul 14, 2023, 5:11 PM EDT - 2 years ago

Cara Therapeutics Faces Uncertainty Despite Potential Reimbursement Extension For Korsuva

Cara Therapeutics to Present at the Jefferies Healthcare Conference

Jun 1, 2023, 7:00 AM EDT - 2 years ago

Cara Therapeutics to Present at the Jefferies Healthcare Conference

Kapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus

May 18, 2023, 2:00 AM EDT - 3 years ago

Kapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus

Cara Therapeutics, Inc. (CARA) Q1 2023 Earnings Call Transcript

May 15, 2023, 7:31 PM EDT - 3 years ago

Cara Therapeutics, Inc. (CARA) Q1 2023 Earnings Call Transcript

Cara Therapeutics Reports First Quarter 2023 Financial Results

May 15, 2023, 4:01 PM EDT - 3 years ago

Cara Therapeutics Reports First Quarter 2023 Financial Results

Cara Therapeutics, Inc. (CARA) to Announce First Quarter 2023 Financial Results on May 15, 2023

May 1, 2023, 9:20 AM EDT - 3 years ago

Cara Therapeutics, Inc. (CARA) to Announce First Quarter 2023 Financial Results on May 15, 2023

Cara Therapeutics to Announce First Quarter 2023 Financial Results on May 15, 2023

May 1, 2023, 7:00 AM EDT - 3 years ago

Cara Therapeutics to Announce First Quarter 2023 Financial Results on May 15, 2023

Cara Therapeutics Announces Presentation at the 22nd Annual Needham Virtual Healthcare Conference

Apr 10, 2023, 7:00 AM EDT - 3 years ago

Cara Therapeutics Announces Presentation at the 22nd Annual Needham Virtual Healthcare Conference

Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month - Cara Therapeutics (NASDAQ:CARA), AdaptHealth (NASDAQ:AHCO)

Mar 14, 2023, 8:02 AM EDT - 3 years ago

Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month - Cara Therapeutics (NASDAQ:CARA), AdaptHealth (NASDAQ:AHCO)

AHCO OPRX TKNO

Cara Therapeutics Releases Inaugural Environmental, Social, and Governance Report

Mar 14, 2023, 7:00 AM EDT - 3 years ago

Cara Therapeutics Releases Inaugural Environmental, Social, and Governance Report

Cara Therapeutics: Looking To Place A Bid After A Big Miss On Earnings

Mar 13, 2023, 9:00 AM EDT - 3 years ago

Cara Therapeutics: Looking To Place A Bid After A Big Miss On Earnings

Cara Therapeutics stock sinks on larger-than-expected Q4 earnings miss

Mar 7, 2023, 10:13 AM EST - 3 years ago

Cara Therapeutics stock sinks on larger-than-expected Q4 earnings miss

Cara Therapeutics, Inc. (CARA) Q4 2022 Earnings Call Transcript

Mar 6, 2023, 8:44 PM EST - 3 years ago

Cara Therapeutics, Inc. (CARA) Q4 2022 Earnings Call Transcript

Cara Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results

Mar 6, 2023, 4:01 PM EST - 3 years ago

Cara Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results

Cara Therapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023

Feb 21, 2023, 7:00 AM EST - 3 years ago

Cara Therapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023

Cara Therapeutics Announces Results from the KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Notalgia Paresthetica Published in the New England Journal of Medicine

Feb 8, 2023, 5:00 PM EST - 3 years ago

Cara Therapeutics Announces Results from the KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Notalgia Paresthetica Published in the New England Journal of Medicine

Cara Therapeutics to Host Capital Markets Day on Thursday, February 16, 2023

Jan 17, 2023, 7:00 AM EST - 3 years ago

Cara Therapeutics to Host Capital Markets Day on Thursday, February 16, 2023

Cara Therapeutics Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference

Jan 3, 2023, 7:00 AM EST - 3 years ago

Cara Therapeutics Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference

Cannabis REITs: Smoked Out

Dec 29, 2022, 11:15 AM EST - 3 years ago

Cannabis REITs: Smoked Out

ACB AFCG BYND CGC CNBS CRON CWEB

Cara Therapeutics, Inc. (CARA) Q3 2022 Earnings Call Transcript

Nov 7, 2022, 8:31 PM EST - 3 years ago

Cara Therapeutics, Inc. (CARA) Q3 2022 Earnings Call Transcript

NoEmotionzTrade
NoEmotionzTrade Feb. 19 at 1:15 AM
AGAE is sitting at a valuation that doesn’t reflect its partnerships or cash position. 3M float cap is nothing. If buyers step in and shorts can’t find shares, this can squeeze toward .50 quickly. $TRVN $GRTX $CARA $ALBT
1 · Reply
liadanielle
liadanielle Feb. 10 at 9:29 PM
$CARA FBIO!!!! Hold this long and make your money back
0 · Reply
liadanielle
liadanielle Feb. 10 at 9:20 PM
$CARA Wow!! I made a lot of money on this stock 3 to 4 years ago buying and selling up and down. They had revolutionary ideas. But I guess they’re shit just don’t work.
0 · Reply
Buckwacker
Buckwacker Jan. 3 at 1:54 AM
$CARA this is down 540 percent in five years I lost 16 k They suck…
0 · Reply
Buckwacker
Buckwacker Dec. 15 at 8:18 PM
$CARA wholly shit!! I haven’t looked at this for a bout a year Reverse split horror show…. 🤦🏻‍♂️
0 · Reply
saudq1978
saudq1978 Oct. 22 at 4:59 PM
$CARA
0 · Reply
Bigprofits23
Bigprofits23 Oct. 16 at 2:06 PM
$CARA Is this the proverbial, “Dead Cat Bounce?”
0 · Reply
saudq1978
saudq1978 Oct. 14 at 4:32 AM
$CARA
0 · Reply
saudq1978
saudq1978 Oct. 14 at 4:32 AM
$CARA
0 · Reply
saudq1978
saudq1978 Oct. 14 at 4:31 AM
$CARA
0 · Reply
Iamthecooler
Iamthecooler Oct. 13 at 5:31 PM
$CARA Bunch of fucking garbage, hope people burn
0 · Reply
FemaleGermanInvestor
FemaleGermanInvestor Oct. 13 at 4:52 PM
$CARA what happened here?
0 · Reply
Matt_1
Matt_1 Oct. 13 at 2:50 PM
$CARA why the massive drop ?! Couldn’t find anything in the news
0 · Reply
flyingcoyote
flyingcoyote Oct. 13 at 1:21 PM
$CARA
0 · Reply
___dog___
___dog___ Sep. 11 at 12:28 AM
$CARA 🤣🤣🤣🤣🤣 up over 350% Are you just a troll non trader? Because you definitely can't make a living at trading
0 · Reply
TheBigSauce
TheBigSauce Jul. 26 at 9:43 PM
$OLB If $OLB clears pivot, volume may mimic the $CARA style squeeze candle.
0 · Reply
Navadel_
Navadel_ Jun. 9 at 9:23 PM
$KLTO $CARA
0 · Reply
mtlewis
mtlewis May. 2 at 1:50 AM
$CARA this company no longer exists. The ticker is now TVRD, so these data are meaningless.
0 · Reply
Alex1183
Alex1183 Apr. 30 at 4:52 PM
$CARA PT is a high of $42 wow 🤯 maybe when I’m 94 yrs old the will be profitable
3 · Reply
Alex1183
Alex1183 Apr. 30 at 3:57 PM
$CARA in only down97% lets see this go to $800
1 · Reply
Estimize
Estimize Apr. 30 at 1:06 PM
Wall St is expecting -2.40 EPS for $CARA Q1 [Reporting 05/13 AMC] http://www.estimize.com/intro/cara?chart=historical&metric_name=eps&utm_c
0 · Reply
Iamthecooler
Iamthecooler Apr. 29 at 9:27 PM
$CARA only 400% to go!
1 · Reply